Genetic Code Cracked For A Devastating Blood Parasite
Scientists have cracked the genetic code and predicted some high priority drug targets for the blood parasite Schistosoma haematobium, which is linked to bladder cancer and HIV/ AIDS and causes the insidious urogenital disease schistosomiasis haematobia in more than 112 million people in Africa. Schistomiasis is recognised by the World Health Organization as one of the most socioeconomically devastating diseases, besides malaria, and is in urgent need of extensive research and improved control.
Tykerb And Herceptin - Their Role In Breast Cancer Treatment Clarified
Patients with HER2-positive breast cancer have been treated with Tykerb (lapatinib) both in combination with herceptin (trastuzumab), and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy. Two new studies on these drugs, one published in The Lancet Oncology and one in The Lancet, have demonstrated that lapatinib appears to be less beneficial than trastuzumab as a single-agent therapy, whilst The Lancet publication reveals that a combination of both drugs seems to be nearly twice as effective as single-agent therapy, even though lapatinib causes more side effects.
Stopping Prostate Cancer Growth - Breakthrough
A study by investigators at the Methodist Research Institute at Indiana University confirms that an all-natural, doctor-designed formula is effective in suppressing prostate cancer tumors. The study conducted on mice, used a human prostate cancer xenograft model. Results from the live animal study were presented by lead researcher, Dr. Daniel Sliva at the 16th World Congress on Advances in Oncology in Rhodes, Greece and at the 14th International Symposium on Molecular Medicine. The formula showed to be considerably effective in suppressing the proliferation and metastasis of human hormone refractory (androgen independent) prostate cancer cells.